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Background: Regular use of aspirin has been associated with a reduced risk of cancer at several sites but the data for
endometrial cancer are conflicting. Evidence regarding use of other analgesics is limited.
Patients and methods: We pooled individual-level data from seven cohort and five case–control studies participating in the
Epidemiology of Endometrial Cancer Consortium including 7120 women with endometrial cancer and 16 069 controls. For
overall analyses, study-specific odds ratios (ORs) and 95% confidence intervals (CI) were estimated using logistic regression and
combined using random-effects meta-analysis; for stratified analyses, we used mixed-effects logistic regression with study as a
random effect.
Results: At least weekly use of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with an
approximately 15% reduced risk of endometrial cancer among both overweight and obese women (OR¼ 0.86 [95% CI 0.76–
0.98] and 0.86 [95% CI 0.76–0.97], respectively, for aspirin; 0.87 [95% CI 0.76–1.00] and 0.84 [0.74–0.96], respectively, for non-
aspirin NSAIDs). There was no association among women of normal weight (body mass index< 25 kg/m2, Pheterogeneity¼ 0.04
for aspirin, Pheterogeneity¼ 0.003 for NSAIDs). Among overweight and obese women, the inverse association with aspirin was
stronger for use 2–6 times/week (OR¼ 0.81, 95% CI 0.68–0.96) than for daily use (0.91, 0.80–1.03), possibly because a high
proportion of daily users use low-dose formulations. There was no clear association with use of acetaminophen.
Conclusion: Our pooled analysis provides further evidence that use of standard-dose aspirin or other NSAIDs may reduce risk
of endometrial cancer among overweight and obese women.
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Introduction
Endometrial cancer, the fourth most common cancer among
women in high-income countries, affects more than 380 000
women worldwide each year [1], including 63 000 in the United
States [2], and age-standardized incidence rates are increasing.
A major risk factor is exposure to estrogen in the absence of a pro-
gestogen [3]; the main source of estrogen in post-menopausal
women is adipose tissue, where aromatase converts androgens to
estrogens. Estimates suggest one in three endometrial cancers are
attributable to overweight and obesity [4].
While regular use of aspirin reduces risk of colorectal and pos-
sibly other cancers [5], data for endometrial cancer are less clear.
Meta-analyses suggest an inverse association that is stronger
among obese women [6–9], but they are susceptible to publica-
tion bias and the included studies varied in their categorization of
medication use and adjustment for confounders. They were also
unable to separate standard from low-dose aspirin, yet individual
studies have reported weaker associations for low-dose aspirin
[6, 10]. It is plausible that anti-inflammatory medications might
be more protective among obese women because obesity is asso-
ciated with chronic low-grade inflammation [11]. Furthermore,
aromatase-mediated conversion of androgens in fat cells is the
primary source of estrogen in post-menopausal women and non-
steroidal anti-inflammatory drugs (NSAIDs) have been shown to
down-regulate aromatase activity in cell lines [12]. By suppress-
ing inflammation and aromatase, NSAIDs may mitigate some of
the excess endometrial cancer risk associated with obesity.
A recent review called for studies pooling data from multiple
sources to clarify the relation between aspirin and endometrial
cancer [13]. To this end, we pooled individual-level data from 12
studies in the Epidemiology of Endometrial Cancer Consortium
(E2C2) to evaluate associations between analgesic use and endo-
metrial cancer risk. Our a priori hypothesis was that use of aspirin
(standard-dose) and other NSAIDs, but not low-dose aspirin or
acetaminophen, would be associated with reduced risk, particu-
larly among obese women.
Methods
We included five case–control and seven cohort studies that provided
data regarding use of aspirin, non-aspirin (NA-) NSAIDs and/or acet-
aminophen (supplementary Table S1, available at Annals of Oncology on-
line). All studies were approved by the relevant institutional review
board(s) and participants provided informed consent.
The E2C2 data harmonization process has been described [14]. In
brief, cohort studies are analyzed as nested case–control studies with up
to four controls per case, matched on year-of-birth, cohort entry date
and other study-specific criteria as appropriate, randomly selected from
cohort members who had not had a hysterectomy or endometrial cancer
by the case diagnosis date. Studies provided information on demograph-
ic, anthropometric, reproductive, medical and lifestyle factors (e.g.
height, weight [see supplementary Table S2, available at Annals of
Oncology online], parity, oral contraceptive (OC) and menopausal
hormone therapy (MHT) use, diabetes, smoking) according to specified
definitions. We excluded cases (and their matched controls) with non-
epithelial tumors or tumors of unknown histology (196 cases/754
controls) and women missing data for aspirin, NA-NSAIDs and acet-
aminophen (814 cases/4977 controls, including controls individually-
matched to cases without data). With the exception of the Breast Cancer
Detection Demonstration Project (BCDDP) where women reported past
and current medication use, cases (and matched controls) diagnosed be-
fore collection of medication data in the cohort studies were also
excluded (344 cases/502 controls). The final study group comprised 7120
cases and 16 069 controls.
Supplementary Table S1, available at Annals of Oncology online shows
the questions used to ascertain medication use in each study. The
Australian National Endometrial Cancer Study (ANECS) asked about
use in the five years before enrolment while the other case–control studies
asked about ever use. For the Iowa Women’s Health Study (IOWA),
Multiethnic Cohort Study (MEC), NIH-AARP Diet and Health Study
(NIH) and Prostate, Lung, Colorectal and Ovarian Cancer Screening
Trial (PLCO), data were collected at baseline and not updated during
follow-up. For the Black Women’s Health Study (BWHS), data were
updated from the most recent questionnaire before a participant became
a case/was selected as a control. Data for the Swedish Women’s Lifestyle
and Health Study (SWLHS) came from the national pharmacy prescrip-
tion database. ‘Regular’ medication use was defined as use at least once/
week, but this definition differed slightly depending on the questions
used to ascertain medication use, for example, BWHS only asked women
to report use of at least 3 days/week. In studies with information about
frequency of use, we further classified women as using the medications
less than once/week, once/week, 2–6 times/week or daily. These cut
points were selected for pragmatic reasons based on categories used in
the original studies and in order to look separately at women who
reported daily aspirin use as this was considered more likely to be low
dose.
Statistical analyses
Analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC,
USA) and Stata version 13 (StataCorp LP, College Station, TX, USA). For
the overall models, pooled odds ratios (pORs) were calculated using a
two-stage method. First, study-specific ORs and 95% confidence inter-
vals (CI) were estimated for the associations between regular use of medi-
cations (yes/no) and risk of endometrial cancer using multivariable
logistic regression (conditional regression for the matched studies).
Models were adjusted for age (continuous), parity, body mass index
(BMI) (kg/m2, continuous) and OC use (ever/never; further adjustment
for OC duration in studies with this information made little difference),
highest level of education (high-school/college/university) and smoking
(never/former/current). See supplementary Methods, available at Annals
of Oncology online, for further details regarding models and handling of
missing data. Study-specific estimates were pooled using random-effects
models and heterogeneity was assessed using I2 and Q statistics.
To address our primary hypothesis that any inverse association with
medication use would be more pronounced among obese women, we
stratified by BMI (normal <25, overweight 25–29.9, obese 30 kg/m2).
We also assessed whether associations differed by study design, race, par-
ity, OC use and, among post-menopausal women, use of MHT, or be-
tween type 1 and type 2 cancers (see supplementary Methods, available at
Annals of Oncology online). For stratified analyses, we used generalized
mixed regression models allowing the exposure effect to vary across stud-
ies [15]. Models were constructed to allow for the individual-level case–
control matching in cohort studies with each unmatched case–control
study treated as a single set (this gave identical estimates to standard un-
conditional models for these studies).
To estimate the potential impact of changing aspirin use if observed
associations were causal, we used the age-standardized incidence rate for
endometrial cancer in the United States [16], the BMI distribution in the
USA female population (33% normal weight, 27% overweight, 40%
obese) [17], and relative risks for overweight and obesity in the study
population (overweight¼ 1.5; obese¼ 3.5) to estimate incidence rates by
BMI. We then used the relative risks for overweight and obese women
who used aspirin (versus all normal weight women, assuming no aspirin
effect in this group) to estimate the potential reduction in incidence and
thus the proportion and number of cancers potentially preventable if all
overweight/obese women took aspirin at least once a week.
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Results
The proportion of controls classified as regular users of aspirin
ranged from 9% to 43% across the studies, NA-NSAIDs from 9%
to 36% and acetaminophen from 15% to 36% (supplementary
Table S1, available at Annals of Oncology online). The prevalence
was lowest in Estrogen, Diet and Genetics of Endometrial Cancer
Study (EDGE) where women were asked to report medications
used continuously for at least 6 months and, for aspirin, the
Swedish study, which only recorded prescription medications.
Aspirin
Overall, there was a borderline significant inverse association be-
tween regular use of aspirin and endometrial cancer risk
(Figure 1A; pOR¼ 0.93, 95% CI 0.86–1.00). There was no signifi-
cant heterogeneity between the studies, but the inverse association
was stronger for case–control (pOR¼ 0.85, 95% CI 0.72–1.01)
than for cohort studies (pOR¼ 0.96, 95% CI 0.88–1.05). Figure 1B
shows no association among women of normal weight, but regular
use of aspirin was associated with a 14% risk reduction among
both overweight (OR¼ 0.86, 95% CI 0.76–0.98) and obese
(OR¼ 0.86, 95% CI 0.76–0.97) women (Pheterogenity¼ 0.04). This
pattern was also seen when we excluded studies that had previously
published results stratified by BMI (OR [95% CI] for BMI< 25
and 25: 1.09 [0.93–1.26] and 0.87 [0.78–0.97]) and when we
stratified by study design (case–control studies 0.95 [0.76–1.19]
and 0.81 [0.68–0.95]; cohort studies 1.10 [0.95–1.26] and 0.89
[0.81–0.99]. Figure 1B also shows that the association was stron-
gest for black women, likely because of a higher prevalence of over-
weight/obesity (77% among controls), than for white (51%) and
Asian (29%) women. The association did not differ significantly by
parity, OC or MHT use, or between type 1 and type 2 cancers.
Table 1 shows that in studies with information about frequency
of use, there was no association between endometrial cancer and
use of aspirin once/week (OR¼ 0.98, 95% CI 0.80–1.20) or daily
(OR¼ 0.96, 95% CI 0.86–1.07), and only a suggestive inverse asso-
ciation with use two to six times/week (OR¼ 0.89, 95% CI 0.78–
1.02). However, among overweight and obese women there was a
significant 19% reduction in risk of endometrial cancer for use 2–6
times/week and a non-significant 9% reduction for daily use. Only
two studies [ANECS and Fred Hutchinson Cancer Research
Center Study (FHCRC)] provided data regarding aspirin dose;
both showed an inverse association with use of standard aspirin
two or more times/week and, combined, the estimates were 0.62
(0.47–0.82) for standard and 1.14 (0.82–1.58) for low-dose aspirin.
Compared with all normal-weight women (assuming no associ-
ation with aspirin use in this group), obese women who did not
use aspirin were 3.6 times as likely to develop endometrial cancer
(pOR¼ 3.63, 95% CI 3.32–3.96), but this was reduced to 3.2 times
for obese women who used aspirin (pOR¼ 3.20, 95% CI 2.88–
3.57). For overweight women the risks were 1.54 (1.41–1.68) for
non-users versus 1.35 (1.20–1.51) for users of aspirin. If the associ-
ation between aspirin use and endometrial cancer is causal, and all
overweight and obese women took aspirin at least once a week, we
estimate that this could translate to a reduction in incidence of up
to 7.5% equivalent to 4600 fewer cases/year in the United States.
Non-aspirin NSAIDs
There was no overall association between regular use of non-
aspirin NSAIDs and risk of endometrial cancer and little
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Figure 1. Forest plots showing adjusted estimates and 95% conﬁdence intervals (CIs) for the association between regular use of aspirin and
risk of endometrial cancer (A) overall, by study design with estimates ordered from smallest to largest and (B) stratiﬁed by participant charac-
teristics and tumor type. The size of the box indicates the weight of the study, the line represents the 95% CI and the diamonds represent
the pooled estimates. OR, odds ratio; EDGE, Estrogen, Diet, Genetics and Endometrial Cancer Study; ANECS, The Australian National
Endometrial Cancer Study; FHCRC, Fred Hutchinson Cancer Research Center Study; CONN, Connecticut Endometrial Cancer Study; PEDS,
Patient Epidemiologic Data System; BWHS, Black Women’s Health Study; NIH, NIH AARP Diet and Health Study; IOWA, Iowa Women’s Health
Study; PLCO, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; MEC, Multiethnic Cohort Study; SWLHS, Swedish Women’s
Lifestyle and Health Study; BCDDP, Breast Cancer Detection Demonstration Project.
Original article Annals of Oncology
312 | Webb et al. Volume 30 | Issue 2 | 2019
D
ow
nloaded from
 https://academ
ic.oup.com
/annonc/article-abstract/30/2/310/5253175 by N
ational Library of H
ealth Sciences user on 02 M
ay 2019
Table 1. Odds ratios (OR) and 95% conﬁdence intervals (CIs) for the association between frequency of aspirin and nonsteroidal anti-inﬂammatory drugs
(NSAID) use and endometrial cancer risk, overall and by body mass index (BMI)
Aspirina Non-aspirin NSAIDsa
Frequency of use Cases Controls Cases Controls
N (%) N (%) ORb (95% CI) N (%) N (%) ORb (95% CI)
Overall
<1/week 3472 (70) 6130 (65) 1.00 (Ref) 3443 (76) 6878 (77) 1.00 (Ref)
1/week 179 (4) 428 (4) 0.98 (0.80–1.20) 124 (3) 319 (3) 0.80 (0.62–1.02)
2–6/week 450 (9) 1114 (12) 0.89 (0.78–1.02) 446 (10) 771 (9) 0.93 (0.81–1.08)
Daily 877 (17) 1790 (19) 0.96 (0.86–1.07) 492 (11) 989 (11) 0.94 (0.82–1.08)
BMI < 25.0 kg/m2
<1/week 919 (71) 2925 (68) 1.00 (Ref) 954 (81) 3277 (80) 1.00 (Ref)
1/week 52 (4) 196 (5) 1.04 (0.74–1.46) 28 (2) 159 (4) 0.65 (0.42–1.01)
2–6/week 128 (10) 495 (11) 1.05 (0.84–1.32) 90 (8) 284 (7) 1.10 (0.84–1.44)
Daily 199 (15) 710 (16) 1.09 (0.90–1.31) 100 (9) 359 (9) 1.19 (0.93–1.53)
BMI  25.0 kg/m2
<1/week 2466 (69) 3108 (62) 1.00 (Ref) 2421 (75) 3493 (74) 1.00 (Ref)
1/week 126 (3) 224 (4) 0.93 (0.72–1.20) 92 (3) 153 (3) 0.88 (0.65–1.19)
2–6/week 312 (9) 600 (12) 0.81 (0.68–0.96) 342 (11) 477 (10) 0.87 (0.73–1.04)
Daily 672 (19) 1066 (21) 0.91 (0.80–1.03) 384 (12) 621 (13) 0.85 (0.73–1.00)
P-trend 0.02
aIncludes the Australian National Endometrial Cancer Study (ANECS), Connecticut Endometrial Cancer Study (CONN), FHCRC, PEDS (aspirin only), Iowa
Women’s Health Study (IOWA), NIH and Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO).
bAdjusted for age at diagnosis/interview (continuous), parity (continuous), BMI (kg/m2, continuous) and oral contraceptive use (ever/never), highest level
of education and smoking.
Study
Case-control studies
EDGE
ANECS
FHCRC
CONN
PEDS
Subtotal (I-squared = 0.0%, P = 0.829)
Subtotal (I-squared = 58.5%, P = 0.025)
Overall (I-squared = 31.3%, P = 0.141)
NOTE: Weights are from random effects analysis
Cohort studies
BWHS
NIH
IOWA
PLCO
MEC
SWLHS
BCDDP
132
1090
298
668
922
141
394
469 4.09
9.20
7.35
10.66
1.08
32.43
0.80 (0.50, 1.30)
0.89 (0.67, 1.19)
1.00 (0.71, 1.40)
1.07 (0.82, 1.38)
1.08 (0.41, 2.85)
0.97 (0.83, 1.13)
0.62 (0.26, 1.45)
0.82 (0.68, 0.99)
0.89 (0.65, 1.22)
0.93 (0.74, 1.15)
0.93 (0.78, 1.10)
1.18 (0.75, 1.86)
1.52 (1.14, 2.04)
0.98 (0.83, 1.15)
1.45
15.18
8.01
12.92
16.43
4.57
9.00
67.57
0.97 (0.87, 1.07) 100.00
1397
408
666
455
Cases %Weight Characteristic
BMI
<25
25-29.9
30+
White
Black
Asian
11
11
8
Race
Parity
Contraceptive use
Menopausal hormone therapy among post-menopausal women
Tumor type
Never
Never
Type 1
Type 2
11
11
Ever estrogen
Combined
8 2263 / 4018
4514 / 12034
779 / 12034
13239 / 3846
205 / 3846
377 / 808
576 / 1658
627 / 1197
152 / 336
250 / 754
8
8
Ever
12
12
3006 / 6525
2404 / 5426
807 / 1894
794 / 1916
0
1-2
3+
12
12
12
1049 / 1570
2181 / 4571
2199 / 5858
334 / 463
626 / 1407
650 / 1962
1.03 (0.85, 1.25)
0.92 (0.82, 1.05)
0.89 (0.79, 1.00)
0.92 (0.83, 1.03)
0.93 (0.83, 1.04)
0.80 (0.70, 0.92)
0.95 (0.74, 1.23)
0.98 (0.81, 1.18)
0.93 (0.86, 1.01)
0.86 (0.72, 1.02)
12
12
12
1620 / 5933
1514 / 3801
2218 / 2146
368 / 1480
396 / 1278
824 / 1042
4513 / 8949 1310 / 2803
331 / 1019 113 / 409
263 / 850 48 / 191
0.97 (0.89, 1.06)
0.79 (0.59, 1.05)
0.78 (0.53, 1.14)
1.11 (0.97, 1.27)
0.87 (0.76, 1.00)
0.84 (0.74, 0.96)
Studies
(N)
NA-NSAIDs use
No
Cases / Controls
Yes pOR (95% CI)
OR (95% CI)
0.3 0.5 1
Odds ratio
1.5 2 0.5 1
Odds ratio
1.5
Figure 2. Forest plots showing adjusted estimates and 95% conﬁdence intervals (CIs) for the association between regular use of non-aspirin
nonsteroidal anti-inﬂammatory drugs (NSAIDs) and risk of endometrial cancer (A) overall, by study design with estimates ordered from small-
est to largest and (B) stratiﬁed by participant characteristics and tumor type. The size of the box indicates the weight of the study, the line
represents the 95% CI and the diamonds represent the pooled estimates. BMI, body mass index; pOR, pooled odds ratios; EDGE, Estrogen,
Diet, Genetics and Endometrial Cancer Study; ANECS, The Australian National Endometrial Cancer Study; FHCRC, Fred Hutchinson Cancer
Research Center Study; CONN, Connecticut Endometrial Cancer Study; PEDS, Patient Epidemiologic Data System; BWHS, Black Women’s
Health Study; NIH, NIH AARP Diet and Health Study; IOWA, Iowa Women’s Health Study; PLCO, Prostate, Lung, Colorectal and Ovarian Cancer
Screening Trial; MEC, Multiethnic Cohort Study; SWLHS, Swedish Women’s Lifestyle and Health Study; BCDDP, Breast Cancer Detection
Demonstration Project.
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difference between case–control and cohort studies, although the
results from cohort studies were very heterogeneous (Figure 2A).
However, similar to aspirin, NA-NSAID use was associated with
a 13% reduction in risk among overweight women and a statistic-
ally significant 16% reduction in risk among obese women
(Figure 2B, Pheterogenity¼ 0.003). The association did not differ
significantly by race, parity, OC or MHT use or for type 1 and
type 2 cancers.
Table 1 shows that in studies with information about frequency
of use, there was no trend with increasing frequency of use overall
or among women with BMI <25, but a suggestive trend toward
lower risk with increasing frequency among women with BMI of
25 kg/m2 or higher (Ptrend¼ 0.02).
Acetaminophen
There was no association between regular use of acetaminophen
and endometrial cancer risk in the seven studies with information
available (supplementary Figure S1A, available at Annals of
Oncology online). Stratification by BMI suggested an inverse asso-
ciation among overweight women (OR¼ 0.79, 95% CI 0.64–0.96)
but no association among normal weight (1.10, 95% CI 0.91–1.33)
or obese women (1.04, 95% CI 0.86–1.24) (supplementary Figure
S1B, available at Annals of Oncology online). Estimates did not dif-
fer appreciably by the other variables considered. Too few studies
had information about frequency of use to assess this.
Discussion
Our a priori hypothesis was that use of standard-dose aspirin and
other NSAIDs would be associated with a reduced risk of endomet-
rial cancer, particularly among obese women, but that there would
be no association with low-dose aspirin or acetaminophen.
Overall, our results largely support this hypothesis. Use of aspirin
2–6 times/week was associated with significantly reduced risk of
endometrial cancer among overweight/obese women, but not
among normal-weight women. Furthermore, the association with
daily aspirin use, which likely includes most low-dose use [18], was
weaker and in the two studies with dose information, the inverse
association was restricted to standard-dose formulations. We also
saw reductions in risk for regular use of non-aspirin NSAIDs
among overweight/obese women, but no clear pattern with acet-
aminophen use. The results did not differ significantly between
type 1 and type 2 cancers, although the associations with type 2
cancers were slightly stronger. Although the potential risk reduc-
tion with aspirin is modest (10%–20%), if this association is causal
and all overweight/obese women used standard-dose aspirin at
least once a week, this could translate into up to 4600 fewer endo-
metrial cancers per year in the United States.
Our results for aspirin are consistent with two meta-analyses
(including seven studies in the current analysis) which reported
modest inverse associations between regular aspirin use and
endometrial cancer among obese women although they could
not distinguish between standard and low-dose use preparations
[7, 9]. One meta-analysis also reported a non-significant risk re-
duction for NSAIDs but did not consider whether this might vary
by BMI [7]. Limited randomized trial evidence is also consistent
with a modest beneficial effect of standard-dose aspirin. A pooled
analysis of data from trials of aspirin to prevent vascular events,
reported no uterine cancers among women randomized to as-
pirin (versus 9 in the placebo group, P¼ 0.003) [19]. Similarly, in
a trial of aspirin among patients with Lynch syndrome, only five
endometrial cancers were diagnosed among 427 women random-
ized to 600 mg aspirin/day (versus 13 among 434 in the placebo
group) [20]. This study also reported that aspirin reduced the ad-
verse effects of obesity on colorectal cancer risk [21]. The weaker
association with daily (presumed to be largely low-dose) aspirin
use in our analysis is consistent with the Women’s Health Study,
which did not show any reduction in endometrial cancer risk
among those randomized to 100 mg aspirin every second day
[22]. Seven studies (ANECS, FHCRC, Patient Epidemiologic
Data System, MEC and three others [23–25]) have previously
reported no clear evidence for an association between acetamino-
phen use and endometrial cancer.
Strengths of our analysis include the large sample size, inclu-
sion of published and unpublished data, and greater ability to
standardize exposure levels and adjust consistently for confound-
ers. Although previous meta-analyses reported inverse associa-
tions between aspirin use and endometrial cancer among obese
women [6, 7, 9], these may be subject to publication bias if studies
that saw no association had not published their data. Our analysis
includes five studies that had not previously published data eval-
uating aspirin use in relation to endometrial cancer (Connecticut
Endometrial Cancer Study, BCDDP, BWHS, PLCO, SWLHS)
and we included 40%–50% more cases for two previously pub-
lished studies (MEC and NIH). Although only two studies pro-
vided information about aspirin dose, we were able to assess this
indirectly by looking separately at daily users who are most likely
to use low-dose preparations.
Limitations of our study include the self-reported nature of the
data for all studies except SWLHS (which used linkage to prescrip-
tions data but could not capture over-the-counter use), and the
possibilities of bias in individual studies. Also, despite the large
sample, numbers were still limited for some sub-group analyses.
Overall, the associations we observed with aspirin use were stron-
ger among the case–control studies than the cohort studies al-
though this difference disappeared when we stratified by BMI.
Although case–control studies might overestimate the strength
of association because of selection or recall bias, changing
medication use over time in cohort studies would lead to misclassi-
fication which could attenuate associations. A systematic compari-
son of studies evaluating aspirin and cancer incidence concluded
that results from case–control studies were highly correlated with
those from randomized trials; in contrast, estimates from cohort
studies were weaker if aspirin use was not updated during follow-
up [26]. The fact that several cohort studies in this analysis did not
update medication use after baseline (IOWA, MEC, NIH, PLCO),
the difference between normal-weight and overweight/obese
women was seen in both case–control and cohort studies, and no
association was seen for acetaminophen, suggests that our results
are not an artefact due to bias in the case-control studies.
An inverse association between use of anti-inflammatory med-
ications and endometrial cancer risk among overweight/obese
women is biologically plausible [27]. Several risk factors for
endometrial cancer, including obesity [11], are associated with
systemic chronic low-grade inflammation. Prospective studies
have reported higher endometrial cancer risks among women
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with higher concentrations of inflammatory markers [28–30]
with one suggesting the risk was greatest for women who were
both obese and had high levels of inflammatory markers [30].
Both aspirin and NSAIDs inhibit cyclooxygenase (COX), leading
to a reduction in prostaglandin levels and, in breast cancer cell
lines, COX inhibitors also down-regulate aromatase activity [12].
Cross-sectional studies suggest post-menopausal women who
regularly use NSAIDs have lower estradiol levels than nonusers
[31, 32]. In vitro studies suggest aspirin and NSAIDs also have
antiproliferative and antineoplastic effects that are independent
of COX inhibition [33, 34] and can inhibit the proliferation of
endometrial cancer cells [35, 36].
In conclusion, our analysis provides further evidence that use
of standard-dose aspirin or other NSAIDs might reduce the risk
of endometrial cancer among overweight and obese women.
Future studies should clarify the relationship with low-dose as-
pirin and should include regularly updated measures of medica-
tion use (dose, frequency), ideally in a well-powered randomized
trial to minimize bias and confounding. If confirmed, clinicians
could consider aspirin or NSAIDs as an option to reduce the
greatly increased risk of endometrial cancer among obese women
who have an intact uterus.
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